Literature DB >> 17684498

Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors.

L M Wiedholz1, W A Owens, R E Horton, M Feyder, R-M Karlsson, K Hefner, R Sprengel, T Celikel, L C Daws, A Holmes.   

Abstract

There is growing evidence implicating dysfunctional glutamatergic neurotransmission and abnormal interactions between the glutamate and dopamine (DA) systems in the pathophysiology of various neuropsychiatric disorders including schizophrenia. The present study evaluated knockout (KO) mice lacking the L-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) GluR1 receptor subunit for a range of behaviors considered relevant to certain symptoms of schizophrenia. KO showed locomotor hyperactivity during exposure to open field and in response to a novel object, but normal activity in a familiar home cage. Open field locomotor hyperactivity in KO was effectively normalized to WT levels by treatment with the DA antagonist and neuroleptic haloperidol, while locomotor stimulant effects of the NMDA receptor antagonist MK-801 were absent in KO. Social behaviors during a dyadic conspecific encounter were disorganized in KO. KO showed deficits in prepulse inhibition of the acoustic startle response. In vivo chronoamperometric measurement of extracellular DA clearance in striatum demonstrated retarded clearance in KO. These data demonstrate behavioral abnormalities potentially pertinent to schizophrenia in GluR1 KO, together with evidence of dysregulated DA function. Present findings provide novel insight into the potential role of GluR1, AMPA receptors and glutamate x DA interactions in the pathophysiology of schizophrenia and other neuropsychiatric conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684498     DOI: 10.1038/sj.mp.4002056

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  84 in total

1.  Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity.

Authors:  O Gunduz-Cinar; K P MacPherson; R Cinar; J Gamble-George; K Sugden; B Williams; G Godlewski; T S Ramikie; A X Gorka; S O Alapafuja; S P Nikas; A Makriyannis; R Poulton; S Patel; A R Hariri; A Caspi; T E Moffitt; G Kunos; A Holmes
Journal:  Mol Psychiatry       Date:  2012-06-12       Impact factor: 15.992

Review 2.  GSK-3β activity and hyperdopamine-dependent behaviors.

Authors:  Yan-Chun Li; Wen-Jun Gao
Journal:  Neurosci Biobehav Rev       Date:  2010-08-18       Impact factor: 8.989

Review 3.  Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies.

Authors:  Emilia H Moscato; Ankit Jain; Xiaoyu Peng; Ethan G Hughes; Josep Dalmau; Rita J Balice-Gordon
Journal:  Eur J Neurosci       Date:  2010-07-14       Impact factor: 3.386

Review 4.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

5.  Fear memory impairing effects of systemic treatment with the NMDA NR2B subunit antagonist, Ro 25-6981, in mice: attenuation with ageing.

Authors:  Poonam Mathur; Carolyn Graybeal; Michael Feyder; Margaret I Davis; Andrew Holmes
Journal:  Pharmacol Biochem Behav       Date:  2008-09-08       Impact factor: 3.533

6.  The schizophrenia susceptibility gene DTNBP1 modulates AMPAR synaptic transmission and plasticity in the hippocampus of juvenile DBA/2J mice.

Authors:  Ian J Orozco; Peter Koppensteiner; Ipe Ninan; Ottavio Arancio
Journal:  Mol Cell Neurosci       Date:  2013-12-07       Impact factor: 4.314

7.  Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioral abnormalities that model symptoms of Schizophrenia.

Authors:  Xiaochuan Guo; Peter J Hamilton; Nicholas J Reish; J David Sweatt; Courtney A Miller; Gavin Rumbaugh
Journal:  Neuropsychopharmacology       Date:  2009-01-14       Impact factor: 7.853

Review 8.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

9.  Role of major NMDA or AMPA receptor subunits in MK-801 potentiation of ethanol intoxication.

Authors:  Benjamin Palachick; Yi-Chyan Chen; Abigail J Enoch; Rose-Marie Karlsson; Masayoshi Mishina; Andrew Holmes
Journal:  Alcohol Clin Exp Res       Date:  2008-06-28       Impact factor: 3.455

Review 10.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.